Isolation of a human single chain antibody fragment against oligomeric α-synuclein that inhibits aggregation and prevents α-synuclein-induced toxicity

被引:128
作者
Emadi, Sharareh [1 ]
Barkhordarian, Hedieh [1 ]
Wang, Min S. [1 ]
Schulz, Philip [1 ]
Sierks, Michael R. [1 ]
机构
[1] Arizona State Univ, Dept Chem & Mat Engn, Tempe, AZ 85287 USA
关键词
Parkinson's Disease; AFM; scFv; alpha-synuclein; phage display;
D O I
10.1016/j.jmb.2007.02.089
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Protein misfolding and aggregation are pathological aspects of numerous and neurodegenerative diseases. Aggregates of alpha-synuclein are major components of the Lewy bodies and Lewy neurites associated with Parkinson's Disease (PD). A natively unfolded protein, alpha-synuclein can adopt different aggregated morphologies, including oligomers, protofibrils and fibrils. The small oligomeric aggregates have been shown to be particularly toxic. Antibodies that neutralize the neurotoxic aggregates without interfering with beneficial functions of monomeric alpha-synuclein can be useful therapeutics. We were able to isolate single chain antibody fragments (scFvs) from a phage displayed antibody library against the target antigen morphology using a novel biopanning technique that utilizes atomic force microscopy (AFM) to image and immobilize specific morphologies of alpha-synuclein. The scFv described here binds only to an oligomeric form of alpha-synuclein and inhibits both aggregation and toxicity of alpha-synuclein in vitro. This scFv can have potential therapeutic value in controlling misfolding and aggregation of alpha-synuclein in vivo when expressed intracellularly in dopaminergic neurons as an intrabody. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1132 / 1144
页数:13
相关论文
共 66 条
  • [1] Baba M, 1998, AM J PATHOL, V152, P879
  • [2] Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies
    Barkhordarian, Hedieh
    Emadi, Sharareh
    Schulz, Philip
    Sierks, Michael R.
    [J]. PROTEIN ENGINEERING DESIGN & SELECTION, 2006, 19 (11) : 497 - 502
  • [3] Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity
    Boder, ET
    Midelfort, KS
    Wittrup, KD
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (20) : 10701 - 10705
  • [4] A structural and functional role for 11-mer repeats in α-synuclein and other exchangeable lipid binding proteins
    Bussell, R
    Eliezer, D
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2003, 329 (04) : 763 - 778
  • [5] Accumulation of insoluble α-synuclein in dementia with Lewy bodies
    Campbell, BCV
    Li, QX
    Culvenor, JG
    Jäkälä, P
    Cappai, R
    Beyreuther, K
    Masters, CL
    McLean, CA
    [J]. NEUROBIOLOGY OF DISEASE, 2000, 7 (03) : 192 - 200
  • [6] IMPROVED OLIGONUCLEOTIDE SITE-DIRECTED MUTAGENESIS USING M13 VECTORS
    CARTER, P
    BEDOUELLE, H
    WINTER, G
    [J]. NUCLEIC ACIDS RESEARCH, 1985, 13 (12) : 4431 - 4443
  • [7] Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from α-synuclein in vitro
    Cohlberg, JA
    Li, J
    Uversky, VN
    Fink, AL
    [J]. BIOCHEMISTRY, 2002, 41 (05) : 1502 - 1511
  • [8] Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease
    Conway, KA
    Harper, JD
    Lansbury, PT
    [J]. NATURE MEDICINE, 1998, 4 (11) : 1318 - 1320
  • [9] Synthetic filaments assembled from C-terminally truncated α-synuclein
    Crowther, RA
    Jakes, R
    Spillantini, MG
    Goedert, M
    [J]. FEBS LETTERS, 1998, 436 (03) : 309 - 312
  • [10] Stabilization of α-synuclein secondary structure upon binding to synthetic membranes
    Davidson, WS
    Jonas, A
    Clayton, DF
    George, JM
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (16) : 9443 - 9449